Skip to main content

Novartis VAY736: A subject, investigator, and sponsor blinded randomized placebo controlled multicenter study to investigate VAY736 in patients with idiopathic pulmonary fibrosis

Clinical Trial Grant
Duke Scholars

Administered By

Medicine, Pulmonary, Allergy, and Critical Care Medicine

Awarded By

Novartis Pharmaceuticals Corporation

Start Date

June 19, 2018

End Date

November 16, 2023
 

Administered By

Medicine, Pulmonary, Allergy, and Critical Care Medicine

Awarded By

Novartis Pharmaceuticals Corporation

Start Date

June 19, 2018

End Date

November 16, 2023